Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients

Lekova, Eleonora, Zelek, Wioleta M., Gower, David, Spitzfaden, Claus, Osuch, Isabelle H., John-Morris, Elen, Stach, Lasse, Gormley, Darren, Sanderson, Andrew, Bridges, Angela, Wear, Elizabeth R., Petit-Frere, Sebastien, Burden, Michael N., Priest, Richard, Wattam, Trevor, Kitchen, Semra J., Feeney, Maria, Davis, Susannah, Morgan, B. Paul ORCID: https://orcid.org/0000-0003-4075-7676 and Nichols, Eva-Maria 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13 , 968206. 10.3389/fimmu.2022.968206

	PDF - Published Version Available under License Creative Commons Attribution. Download (11MB)
	PDF - Supplemental Material Available under License Creative Commons Attribution. Download (2MB)
	PDF - Supplemental Material Available under License Creative Commons Attribution. Download (260kB)
	PDF - Supplemental Material Available under License Creative Commons Attribution. Download (1MB)

Abstract

Myasthenia Gravis (MG) is mediated by autoantibodies against acetylcholine receptors that cause loss of the receptors in the neuromuscular junction. Eculizumab, a C5-inhibitor, is the only approved treatment for MG that mechanistically addresses complement-mediated loss of nicotinic acetylcholine receptors. It is an expensive drug and was approved despite missing the primary efficacy endpoint in the Phase 3 REGAIN study. There are two observations to highlight. Firstly, further C5 inhibitors are in clinical development, but other terminal pathway proteins, such as C7, have been relatively understudied as therapeutic targets, despite the potential for lower and less frequent dosing. Secondly, given the known heterogenous mechanisms of action of autoantibodies in MG, effective patient stratification in the REGAIN trial may have provided more favorable efficacy readouts. We investigated C7 as a target and assessed the in vitro function, binding epitopes and mechanism of action of three mAbs against C7. We found the mAbs were human, cynomolgus monkey and/or rat cross-reactive and each had a distinct, novel mechanism of C7 inhibition. TPP1820 was effective in preventing experimental MG in rats in both prophylactic and therapeutic dosing regimens. To enable identification of MG patients that are likely to respond to C7 inhibition, we developed a patient stratification assay and showed in a small cohort of MG patients (n=19) that 63% had significant complement activation and C7-dependent loss of AChRs in this in vitro set up. This study provides validation of C7 as a target for treatment of MG and provides a means of identifying patients likely to respond to anti-C7 therapy based on complement-activating properties of patient autoantibodies.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/
Publisher:	Frontiers Media
Date of First Compliant Deposit:	21 September 2022
Date of Acceptance:	19 July 2022
Last Modified:	11 Oct 2023 20:35
URI:	https://orca.cardiff.ac.uk/id/eprint/152771

Actions (repository staff only)

Edit Item